TITLE

Epimacular radiation and anti-VEGF therapy may help ill current treatment gaps

AUTHOR(S)
Bechtel, Bryan
PUB. DATE
December 2009
SOURCE
Ocular Surgery News;12/10/2009, Vol. 27 Issue 23, p18
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a phase 2 clinical trial which shows potential for combined brachytherapy and anti-VEGF in the treatment of wet age-related macular degeneration. The multicenter study involved 34 patients who were administered with strontium-90 radiation via epimacular brachytherapy and two doses of Avastin. The efficacy of the combined therapy is explained by Doctor Pravin U. Dugel.
ACCESSION #
45566923

 

Related Articles

  • Update: Phase II study outcomes encouraging for treating exudative AMD with combination therapy. Guttman, Cheryl // Ophthalmology Times;11/15/2008, Vol. 33 Issue 22, p18 

    The article cites key findings from an 18-month phase II clinical trial in the U.S. indicating that the combination of epiretinal brachytherapy and bevacizumab is an effective and safe way to treat exudative age-related macular degeneration (AMD). The combination therapy also minimizes the need...

  • Study examines brachytherapy, anti-VEGF for neovascularization secondary to AMD.  // Ocular Surgery News;11/10/2009, Vol. 27 Issue 21, p36 

    The article discusses the results of a prospective, nonrandomized multicenter trial which examined the safety and efficacy of the concomitant delivery of epiretinal brachytherapy and bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration, which...

  • Radiation lowers treatment burden. Charters, Lynda // Ophthalmology Times;5/15/2012, p27 

    The article discusses the results of the Macular EpiRetinal Brachytherapy In Treated Age Related Macular Degeneration Patients (MERITAGE) Study. It states that the MERITAGE Study was aimed at determining the role of epimacular brachytherapy in decreasing the treatment burden in managing...

  • Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. Tufail, Adnan; Patel, Praveen J.; Egan, Catherine; Hykin, Philip; da Cruz, Lyndon; Gregor, Zdenek; Dowler, Jonathan; Majid, Mohammed A.; Bailey, Clare; Mohamed, Quresh; Johnston, Robert; Bunce, Catey; Wen Xing // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/26/2010, Vol. 340 Issue 7761, p1398 

    The article presents a prospective, double blinded, multicentre randomised controlled trial which examined the effectiveness of bevacizumab for treating neovascular age related macular degeneration. It was observed that patients in the bevacizumab group gained 15 or more letters of visual acuity...

  • SalutarisMD Announces Positive Study Results for a New Investigational Wet AMD Therapy.  // Biomedical Market Newsletter;1/21/2012, Vol. 21, p1 

    The article informs about the release of results of positive Phase I data from a human study designed to assess a new investigational therapy to treat Wet Age-related Macular Degeneration (Wet AMD) by Salutaris Medical Devices Inc. The company has developed the minimally invasive device and...

  • New drugs halt vision loss and boost sight for patients with AMD. Sibal, Meg // Filipino Reporter;3/23/2012, Vol. 40 Issue 16, p25 

    The article focuses on a new therapies for patients with age-related macular degeneration (AMD), which was published in the April 2012 issue of Cleveland Clinic Men's "Health Advisor." AMD is the breakdown of the macula that in turns causes blind spots in the central vision and it is categorized...

  • Bevacizumab for the treatment of neovascular age related macular degeneration. Chakravarthy, Usha // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/26/2010, Vol. 340 Issue 7761, p1370 

    The author analyzes the effectiveness of bevacizumab in treating neovascular age related macular degeneration. He notes that ophthalmologists administered the drug intravenously at first but soon changed it to intraocular delivery due to potential systemic adverse events of intravenous...

  • Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. Martin, Daniel F.; Maguire, Maureen G.; Gui-shuang Ying; Grunwald, Juan E.; Fine, Stuart L.; Jaffe, Glenn J. // New England Journal of Medicine;5/19/2011, Vol. 364 Issue 20, p1897 

    Background: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. Methods: In a multicenter, single-blind,...

  • A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Potter, M. J.; Claudio, C. C.; Szabo, S. M. // British Journal of Ophthalmology;Feb2010, Vol. 94 Issue 2, p174 

    Aim To determine if reduced light-dose photodynamic therapy (PDT) combined with bevacizumab will decrease the number of bevacizumab treatments required over 6 months compared with bevacizumab monotherapy in neovascular age-related macular degeneration (AMD). Methods Thirty-six patients with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics